Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipeline targeting cancer and autoimmune diseases.
The financing includes $41 million raised at the company’s inception in August 2025, co-led by HSG, Apricot Capital, and Yuanbio Venture Capital, with participation from 5Y Capital, Co-Win Ventures, Med-Fine Capital, and Hony Capital. The company later secured a $27.7 million extension round co-led by MPCi and Centurium Capital, with additional backing from Lilly Asia Ventures and Eisai Innovation, along with existing investors.
The funding will support the development of Excalipoint’s three proprietary platforms, TOPAbody, T-Cell Immune Shield, and TCE Probody, as well as a pipeline of six differentiated programs designed to improve the efficacy, safety, and durability of T-cell immunotherapies. These programs target solid tumors, difficult-to-treat cancers, and immunological diseases.
Excalipoint’s approach focuses on overcoming key limitations in T-cell engager therapies, including improving activity in “cold” tumors, addressing the tumor microenvironment, and enabling targeting of challenging tumor antigens. The company is building a diversified pipeline to reduce single-asset risk and support future partnerships and licensing opportunities.
The pipeline includes EXP011, a tri-specific antibody targeting DLL3, CD3, and 4-1BB, currently in Phase I/II clinical trials for small cell lung cancer and other malignancies. Additional candidates include EXP012 for gastrointestinal cancers, EXP016 and EXP017 for solid tumors, EP101 targeting tumor-associated antigens, and EXP015 for immunological diseases.
Excalipoint was co-founded by Lei Fang, Ph.D., who serves as Chairman and Chief Executive Officer, and Jielun Zhu, MBA, CFA, who serves as Chief Financial Officer and Chief Business Officer. The company operates under a China NewCo model, combining experienced leadership, capital, and pipeline assets to accelerate drug development and clinical progress.
Since its founding, Excalipoint has rapidly expanded its platform capabilities and pipeline, positioning itself as a multi-platform biotechnology company focused on next-generation immunotherapies.
KEY QUOTES:
“Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers. By combining science and capital with China’s clinical development efficiency and access to large patient populations, we can rapidly generate clinical data while advancing a pipeline of differentiated therapies. Our progress reflects the strength and maturity of China’s biotech ecosystem, which has become an essential part of the global innovation value chain. The strong support from top-tier investors validates both our science and this new approach to building a globally competitive biotechnology company.”
Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics
“Our successful launch and backing from top-tier investors highlight Excalipoint’s strong growth potential. In just six months, we added two technology platforms and expanded our pipeline to six differentiated programs. Built on a NewCo model, we are combining disciplined capital deployment, focused execution, and cross-border partnerships to efficiently translate our science into clinical progress and long-term value.”
Jielun Zhu, MBA, CFA, Co-Founder, Chief Financial Officer and Chief Business Officer, Excalipoint Therapeutics
“MPCi is deeply engaged in healthcare, focusing on science-driven innovative enterprises with core technological barriers. Excalipoint is our highly recognized next-generation TCE innovation powerhouse. With three independent and cutting-edge technology platforms, it has the potential to break down traditional TCE treatment bottlenecks. It boasts 6 highly differentiated pipelines and the rapid clinical progress of EXP011, the lead asset, reflects the team’s exceptional competence and flawless execution. As its long-term partner, MPCi will empower Excalipoint to unlock the enormous value of T-cell immunotherapy and become a global innovation benchmark.”
David Su, Founding Managing Partner, MPCi
“Centurium Capital’s investment thesis focuses on identifying companies capable of driving transformative innovation, and we believe Excalipoint is among the most promising next-generation TCE companies globally. Led by Dr. Lei Fang and Mr. Jielun Zhu, the company combines strong scientific leadership, a differentiated pipeline, and an impressive track record of execution. We are proud to co-lead this financing and support Excalipoint’s continued growth.”
Vicky Li, Executive Director, Centurium Capital
